Vivos Inc Receivables Turnover Ratio (RDGL), from the first quarter 2026 to the first quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Vivos Inc  (RDGL)
 

Vivos Inc Accounts Receivables Turnover Ratio from the first quarter 2026 to the first quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Vivos Inc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 6.48, this represents a new company high. This is a clear indication for improving liquidity at Vivos Inc's clients. Average receivable collection period, for the Vivos Inc in Mar 31 2026 quarter, has decreased to 56 days, compared to 65 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 264 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2039, from overall ranking in the fourth quarter 2025 at 3295.

What is Receivable Turnover Ratio?
What is Vivos Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RDGL Receivables Turnover Ratio (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Receivable Change -11.9 % 116.26 % -6.02 % -1.7 % 24.34 %
Y / Y Revenue Change 34.84 % 892.06 % -62.42 % 11.11 % -
Receivable Turnover Ratio (TTM) 6.48 5.58 4.99 5.28 5.09
RDGL's Total Ranking # 2039 # 3295 # 3620 # 3503 # 2409
Accounts Receivable average collection period days 56 65 73 69 72
Seq. Receivable Change -65.66 % 375.23 % -64.59 % 52.46 % -15.71 %
Seq. Revenue Change 45.72 % 1217.3 % -87.47 % -43.92 % 972.06 %


Receivable Turnover Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 102
Healthcare Sector # 265
Overall Market # 2039

Receivable Turnover Ratio Statistics
High Average Low
6.48 4.5 2.83
(Mar 31 2026)   (Sep 30 2022)





RDGL Company Profile • Back to RDGL Efficiency Comparisons • Compare RDGL Receivables Turnover Ratio to its Competitors

Financial Statements
Vivos Inc's Accounts Receivable $ 0 Millions Visit RDGL's Balance sheet
Vivos Inc's Sales TTM $ 0 Millions Visit RDGL's Income Statement
Sources of RDGL's Revenues Visit RDGL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RDGL's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RDGL's Growth Rates RDGL's Roa RDGL's Inventory Turnover Ratio RDGL's Dividend Comparisons
RDGL's Profitability Ratios RDGL's Roi RDGL's Asset Turnover Ratio RDGL's Dividend Growth
RDGL's Valuation Ratios RDGL's Roe RDGL's Financial Strength Ratios RDGL's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Mar 31 2026 Receivable at quarter ending Mar 31 2026
Cv Sciences Inc   27.37 $ 11.925  Millions$ 0.436  Millions
Wave Life Sciences Ltd   27.36 $ 88.173  Millions$ 3.223  Millions
Safe Pro Group Inc   27.29 $ 1.642  Millions$ 0.060  Millions
Atara Biotherapeutics Inc   27.03 $ 23.540  Millions$ 0.871  Millions
Biorestorative Therapies Inc   25.41 $ 0.363  Millions$ 0.014  Millions
Kiniksa Pharmaceuticals International Plc  24.63 $ 754.045  Millions$ 30.618  Millions
Polomar Health Services, Inc.  24.47 $ 1.649  Millions$ 0.067  Millions
Igc Pharma Inc   23.44 $ 1.166  Millions$ 0.050  Millions
Cytomx Therapeutics Inc   23.09 $ 35.542  Millions$ 1.539  Millions
Siga Technologies Inc  22.41 $ 93.777  Millions$ 4.186  Millions
Ataibeckley Inc   21.56 $ 3.488  Millions$ 0.162  Millions
Fonar Corporation  21.15 $ 105.338  Millions$ 4.981  Millions
Neuraxis Inc   20.94 $ 4.282  Millions$ 0.204  Millions
Vystar Corporation  20.58 $ 0.048  Millions$ 0.002  Millions
Lifemd Inc   19.91 $ 177.869  Millions$ 8.934  Millions
Longeveron Inc   19.07 $ 1.216  Millions$ 0.064  Millions
Premier Air Charter Holdings Inc   18.93 $ 33.205  Millions$ 1.754  Millions
Sonida Senior Living Inc   18.82 $ 411.850  Millions$ 21.878  Millions
Voyager Therapeutics Inc   17.99 $ 36.494  Millions$ 2.029  Millions
China Pharma Holdings Inc  17.15 $ 3.992  Millions$ 0.233  Millions
Nutriband Inc   16.79 $ 1.803  Millions$ 0.107  Millions
Bioage Labs Inc   15.90 $ 10.316  Millions$ 0.649  Millions
Arvinas Inc   15.15 $ 89.400  Millions$ 5.900  Millions
Nurix Therapeutics Inc   15.11 $ 71.779  Millions$ 4.750  Millions
Lexicon Pharmaceuticals Inc   14.91 $ 69.643  Millions$ 4.670  Millions
Vaxart Inc   14.88 $ 255.609  Millions$ 17.175  Millions
Qhslab Inc   14.80 $ 2.775  Millions$ 0.188  Millions
Nexgel Inc   14.19 $ 10.382  Millions$ 0.732  Millions
10x Genomics Inc   14.18 $ 637.614  Millions$ 44.950  Millions
Sutro Biopharma Inc   14.04 $ 99.608  Millions$ 7.095  Millions

Date modified: 2026-10-05T11:03:40+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.